104 research outputs found
Urinary tract infections in pregnancy (review)
Urinary tract infections in pregnancy are common in obstetric practice. This urological pathology is recorded in about every third pregnant woman. There is no trend forward to decline the disease prevalence. Moreover, the number of pregnant women with kidney diseases has increased 4 times over the last 20 years. The best practice for diagnosis of urinary tract infections is urine culture test, which is considered to be the most reliable and accurate diagnostic. According to Order No. 572n by the Ministry of Public Health of the Russian Federation dated 01.11.2012, the procedure is carried out for all pregnant women started from 14 weeks of pregnancy. The necessity for early diagnostics and treatment of urinary tract infections in pregnancy is obvious, since there is a risk of the infection negative impact on a mother and a fetus, course of pregnancy, childbirth and postpartum period. Antibacterial therapy is a method of choice and should be administrated taking into account criteria of safety and tolerability (Food And Drug Administration criteria). Taking into account that antibiotics administration is often empiric, the constant dynamic monitoring of the structure of uropathogens and antimicrobial resistance having specific local features is required
4-Methylumbeliferone Treatment at a Dose of 1.2 g/kg/Day Is Safe for Long-Term Usage in Rats
4-methylumbelliferone (4MU) has been suggested as a potential therapeutic agent for a wide range of neurological diseases. The current study aimed to evaluate the physiological changes and potential side effects after 10 weeks of 4MU treatment at a dose of 1.2 g/kg/day in healthy rats, and after 2 months of a wash-out period. Our findings revealed downregulation of hyaluronan (HA) and chondroitin sulphate proteoglycans throughout the body, significantly increased bile acids in blood samples in weeks 4 and 7 of the 4MU treatment, as well as increased blood sugars and proteins a few weeks after 4MU administration, and significantly increased interleukins IL10, IL12p70 and IFN gamma after 10 weeks of 4MU treatment. These effects, however, were reversed and no significant difference was observed between control treated and 4MU-treated animals after a 9-week wash-out period
Does working memory training have to be adaptive?
This study tested the common assumption that, to be most effective, working memory (WM) training should be adaptive (i.e., task difficulty is adjusted to individual performance). Indirect evidence for this assumption stems from studies comparing adaptive training to a condition in which tasks are practiced on the easiest level of difficulty only [cf. Klingberg (Trends Cogn Sci 14:317-324, 2010)], thereby, however, confounding adaptivity and exposure to varying task difficulty. For a more direct test of this hypothesis, we randomly assigned 130 young adults to one of the three WM training procedures (adaptive, randomized, or self-selected change in training task difficulty) or to an active control group. Despite large performance increases in the trained WM tasks, we observed neither transfer to untrained structurally dissimilar WM tasks nor far transfer to reasoning. Surprisingly, neither training nor transfer effects were modulated by training procedure, indicating that exposure to varying levels of task difficulty is sufficient for inducing training gains
Odd Chain Fatty Acids; New Insights of the Relationship Between the Gut Microbiota, Dietary Intake, Biosynthesis and Glucose Intolerance
Recent findings have shown an inverse association between circulating C15:0/C17:0 fatty acids with disease risk, therefore, their origin needs to be determined to understanding their role in these pathologies. Through combinations of both animal and human intervention studies, we comprehensively investigated all possible contributions of these fatty acids from the gut-microbiota, the diet, and novel endogenous biosynthesis. Investigations included an intestinal germ-free study and a C15:0/C17:0 diet dose response study. Endogenous production was assessed through: a stearic acid infusion, phytol supplementation, and a Hacl1 mouse model. Two human dietary intervention studies were used to translate the results. Finally, a study comparing baseline C15:0/C17:0 with the prognosis of glucose intolerance. We found that circulating C15:0/C17:0 levels were not influenced by the gut-microbiota. The dose response study showed C15:0 had a linear response, however C17:0 was not directly correlated. The phytol supplementation only decreased C17:0. Stearic acid infusion only increased C17:0. Hacl1 only decreased C17:0. The glucose intolerance study showed only C17:0 correlated with prognosis. To summarise, circulating C15:0 and C17:0 are independently derived; C15:0 correlates directly with dietary intake, while C17:0 is substantially biosynthesized, therefore, they are not homologous in the aetiology of metabolic disease. Our findings emphasize the importance of the biosynthesis of C17:0 and recognizing its link with metabolic disease.The authors are grateful to the Medical Research Council for core funding (Lipid Profiling and Signalling programme grant; number UD99999906, Cambridge Lipidomics Biomarker Research Initiative; grant G0800783, MRC Human Nutrition Research PhD programme). Grant GAČR: GA15–09518S and grant Czech Science Foundation GACR: 16-06326S funded part of the gut microbiota investigation. The authors would like to acknowledge the USDA (ACNC-USDA-CRIS 6251-51000-005-03S) for funding of the dose response animal study within this manuscript. The Human study “Dairy Fat supplementation” was supported by research grants from the Hospices Civils de Lyon (Actions Incitatives); from the Programme Hospitalier de Recherche Clinique Interregional; from the Agence Nationale de la Recherche (Programme de Recherche en Nutrition Humaine and the Programme National de Recherche en Alimentation); and from the Innovation Stratégique Industrielle program of the Agence pour l’Innovation OSEO (Innovation Thérapeutique – Diabète project). K. Seyssel and M. Alligier were recipients of a doctoral fellowship from the Ministère de l’Enseignement Supérieur et de la Recherche (France). The phytol supplementation animal study was supported by grants from the Academy of Finland (138690), the Sigrid Juselius Foundation and NordForsk under the Nordic Centres of Excellence Programme in Food, Nutrition and Health, project “Mitohealth” (070010). The NIH Grant R01-DK-18243 for funding of the canine study. HACL1 knockout mouse model was supported by grants from the Flemish “Fonds Wetenschappelijk Onderzoek” (G.0721.10N) and KU Leuven (OT/14/100)
Memória de orientação espacial: avaliação em pacientes com doença de Alzheimer e com epilepsia mesial temporal refratária
The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke
- …